Navidea Biopharmaceuticals, Inc. (NAVBQ)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
At close: Oct 17, 2025
NAVBQ Revenue
Navidea Biopharmaceuticals had revenue of $610 in the twelve months ending September 30, 2023, down -99.47% year-over-year. In the year 2022, Navidea Biopharmaceuticals had annual revenue of $65.65 thousand, down -87.65%.
Revenue (ttm)
610.00
Revenue Growth
-99.47%
P/S Ratio
16.39
Revenue / Employee
46.92
Employees
13
Market Cap
10.00K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 65.65K | -465.86K | -87.65% |
| Dec 31, 2021 | 531.51K | -383.50K | -41.91% |
| Dec 31, 2020 | 915.01K | 257.19K | 39.10% |
| Dec 31, 2019 | 657.83K | -511.53K | -43.74% |
| Dec 31, 2018 | 1.17M | -641.09K | -35.41% |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Federal National Mortgage Association | 28.89B |
| Federal Home Loan Mortgage | 22.97B |
| First National of Nebraska | 1.89B |
| Central Bancompany | 914.42M |
| Procaps Group | 423.75M |
| Wilson Bank Holding Company | 197.85M |
| Wilhelmina International | 18.03M |
| IPE Universal | 17.33M |
Navidea Biopharmaceuticals News
- 10 days ago - Navidea Biopharmaceuticals, Inc. Files for Bankruptcy - Business Wire
- 5 months ago - Navidea Biopharmaceuticals, Inc. Announces Extension of Authority to Implement a Reverse Stock Split - Business Wire
- 7 months ago - Navidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax Assets - Business Wire
- 1 year ago - Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024 - Business Wire
- 1 year ago - Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024 - Business Wire
- 1 year ago - Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations - Business Wire
- 2 years ago - Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release - Business Wire
- 2 years ago - Navidea Biopharmaceuticals, Inc. Announces NYSE American's Decision to Suspend Trading In Its Common Stock - Business Wire